TWI635862B - 使用tor激酶抑制劑之癌症治療 - Google Patents

使用tor激酶抑制劑之癌症治療 Download PDF

Info

Publication number
TWI635862B
TWI635862B TW102109151A TW102109151A TWI635862B TW I635862 B TWI635862 B TW I635862B TW 102109151 A TW102109151 A TW 102109151A TW 102109151 A TW102109151 A TW 102109151A TW I635862 B TWI635862 B TW I635862B
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
methyl
pyrazine
dihydropyrazino
Prior art date
Application number
TW102109151A
Other languages
English (en)
Chinese (zh)
Other versions
TW201343165A (zh
Inventor
徐水禪
克利斯坦 梅耶 黑格
海瑟 雷蒙
拉瑪K 娜爾拉
Original Assignee
美商標誌製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商標誌製藥公司 filed Critical 美商標誌製藥公司
Publication of TW201343165A publication Critical patent/TW201343165A/zh
Application granted granted Critical
Publication of TWI635862B publication Critical patent/TWI635862B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW102109151A 2012-03-15 2013-03-14 使用tor激酶抑制劑之癌症治療 TWI635862B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261611374P 2012-03-15 2012-03-15
US61/611,374 2012-03-15
US201261715331P 2012-10-18 2012-10-18
US61/715,331 2012-10-18

Publications (2)

Publication Number Publication Date
TW201343165A TW201343165A (zh) 2013-11-01
TWI635862B true TWI635862B (zh) 2018-09-21

Family

ID=48014333

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102109151A TWI635862B (zh) 2012-03-15 2013-03-14 使用tor激酶抑制劑之癌症治療

Country Status (19)

Country Link
US (2) US20130245027A1 (enExample)
EP (1) EP2825169B1 (enExample)
JP (2) JP2015511963A (enExample)
KR (1) KR102057359B1 (enExample)
CN (1) CN104271139A (enExample)
AU (1) AU2013202993B2 (enExample)
BR (1) BR112014022707A2 (enExample)
CA (1) CA2867348A1 (enExample)
ES (1) ES2678250T3 (enExample)
IL (1) IL234641B (enExample)
MX (1) MX360880B (enExample)
MY (1) MY178012A (enExample)
NI (1) NI201400112A (enExample)
NZ (1) NZ628407A (enExample)
PH (1) PH12014502046B1 (enExample)
SG (1) SG11201405724RA (enExample)
TW (1) TWI635862B (enExample)
WO (1) WO2013138553A1 (enExample)
ZA (1) ZA201406701B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
WO2014172432A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
TWI654979B (zh) 2013-04-17 2019-04-01 美商標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
KR102459285B1 (ko) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
WO2014172431A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ,エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN112933088B (zh) * 2021-02-03 2022-02-22 南华大学附属第一医院 Y041-5921在制备抗肿瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245611A (zh) * 2008-10-27 2011-11-16 西格诺药品有限公司 用于与 mTOR/PI3K/AKT/途径相关的肿瘤适应症和疾病的 mTOR激酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140104060A (ko) 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
ZA200902384B (en) 2006-10-19 2010-07-28 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2009126926A2 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245611A (zh) * 2008-10-27 2011-11-16 西格诺药品有限公司 用于与 mTOR/PI3K/AKT/途径相关的肿瘤适应症和疾病的 mTOR激酶抑制剂

Also Published As

Publication number Publication date
ZA201406701B (en) 2016-05-25
NZ628407A (en) 2016-04-29
KR102057359B1 (ko) 2019-12-18
JP2015511963A (ja) 2015-04-23
EP2825169B1 (en) 2018-05-09
AU2013202993A1 (en) 2013-10-03
JP6470820B2 (ja) 2019-02-13
US20130245027A1 (en) 2013-09-19
WO2013138553A1 (en) 2013-09-19
AU2013202993B2 (en) 2015-09-03
CN104271139A (zh) 2015-01-07
SG11201405724RA (en) 2014-10-30
HK1201753A1 (en) 2015-09-11
EP2825169A1 (en) 2015-01-21
KR20140138951A (ko) 2014-12-04
TW201343165A (zh) 2013-11-01
JP2018052963A (ja) 2018-04-05
PH12014502046A1 (en) 2014-12-10
MY178012A (en) 2020-09-29
NI201400112A (es) 2015-01-15
CA2867348A1 (en) 2013-09-19
MX2014011118A (es) 2015-04-08
BR112014022707A2 (pt) 2020-10-27
PH12014502046B1 (en) 2020-10-16
US20230338370A1 (en) 2023-10-26
ES2678250T3 (es) 2018-08-09
IL234641A0 (en) 2014-11-30
MX360880B (es) 2018-11-21
IL234641B (en) 2020-04-30

Similar Documents

Publication Publication Date Title
TWI635862B (zh) 使用tor激酶抑制劑之癌症治療
TWI622395B (zh) 使用tor之激酶抑制劑之癌症治療
TWI583385B (zh) 使用tor之激酶抑制劑之癌症治療
TWI600428B (zh) 使用tor激酶抑制劑之癌症治療
TW201733585A (zh) 以tor激酶抑制劑治療癌症
SG183155A1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
US20160008356A1 (en) Treatment of cancer with tor kinase inhibitors
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1201753B (en) Treatment of cancer with tor kinase inhibitors